Followers | 83 |
Posts | 16213 |
Boards Moderated | 3 |
Alias Born | 12/02/2007 |
Monday, February 12, 2018 8:45:35 AM
Fourth Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million
February 12, 2018 06:30 ET Source: ChromaDex Corporation
IRVINE, Calif., Feb. 12, 2018 -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing selected preliminary fourth quarter and full year 2017 results.
Based on preliminary unaudited information, ChromaDex expects to report net revenues for the fourth quarter of 2017 of approximately $7.5 million, up 69% compared to $4.5 million from continuing operations in the fourth quarter of 2016. The increase in fourth quarter revenues was driven by growth in sales of TRU NIAGEN®. For the full year 2017, net revenues are expected to be approximately $21.2 million from continuing operations, down 2% compared to $21.7 million in 2016 as the Company shifted to an integrated global, consumer facing nutraceutical company.
An operating loss for the fourth quarter of 2017 is expected to be in a range of $8.5 million to $9.5 million, compared to a loss of $2.2 million from continuing operations in the fourth quarter of 2016. For the full year 2017, the operating loss from continuing operations is expected to be in a range of $16 million to $17 million, compared to a loss of $2.9 million in 2016. The higher losses in the fourth quarter and full year were the result of the strategic decision to invest ahead of growth in marketing expenditures, as well as higher legal costs associated with ongoing litigation and higher stock-based compensation expense.
Following the strategic shift of the Company, the Company made significant progress in 2017, ChromaDex:
Increased TRU NIAGEN® brand revenue to a majority of total NIAGEN® related revenues in the second half of the year;
Continued the international expansion of the TRU NIAGEN® brand with the successful launch in Hong Kong and Macau in 2017, followed by a first quarter 2018 launch in Singapore;
Sold the laboratory business in 2017 for $7.5 million;
Raised $48 Million from strategic investors, including an affiliate of Mr. Li Ka-Shing, and high-profile venture capitalists;
Strengthened the management team, scientific advisory board, and board of directors, and;
Continued to build the science with 11 publications on NIAGEN®.
“We expected to see our new business model accelerate growth in revenues and gross profits, and this is exactly what we saw in the fourth quarter,” said Frank Jaksch, Jr., CEO and co-founder of ChromaDex. “We look forward to continued validation of our science in the coming months and years.”
Rob Fried, President and Chief Operating Officer of ChromaDex commented: “Our revenue continued to exceed our expectations led by TRU NIAGEN. We continue to believe in the global opportunity to expand the TRU NIAGEN brand, and we expect TRU NIAGEN to continue to grow significantly in 2018."
Recent CDXC News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 12:32:40 PM
- ChromaDex Appoints Ozan Pamir as Chief Financial Officer • Business Wire • 09/20/2024 12:32:00 PM
- ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics • Business Wire • 09/10/2024 12:32:00 PM
- ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions • Business Wire • 09/09/2024 12:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 11:06:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/23/2024 03:52:27 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 • Business Wire • 08/23/2024 12:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:15:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:15:03 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 10:06:58 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 10:05:57 AM
- ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ • Business Wire • 08/19/2024 12:32:00 PM
- ChromaDex Corporation Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:02:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:01:36 PM
- ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference • Business Wire • 08/05/2024 12:32:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 08:52:56 PM
- ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 • Business Wire • 07/24/2024 12:34:00 PM
- ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) • Business Wire • 07/23/2024 12:32:00 PM
- ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel • Business Wire • 07/22/2024 12:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:00:18 PM
- ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August • Business Wire • 07/16/2024 12:34:00 PM
- ChromaDex to Join Russell 2000® Index • Business Wire • 07/01/2024 12:32:00 PM
- Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) • Business Wire • 06/24/2024 12:32:00 PM
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) • Business Wire • 06/13/2024 12:32:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM